But the company, until last year, the most precious in Europe, has seen its stock market escape during the last year in the middle of increased competition and disappointing test results for its new generation treatments.
“However, changes are made to the light of the recent market challenges that Novo Nordisk has faced and the development of the company’s action since mid-2010,” said Novo Nordisk in a statement.
Novo sells the majority of his drugs against obesity in the United States where President Donald Trump has depreciated the high price responsible for it, recently contrasting at a price much lower than the United Kingdom, Trump has signed a decree of this week to reduce medication costs.
In Brussels, Jørgensen is president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Pharmaceutical Lobby in the EU.
Jørgensen, who has been working in the company since 1991, told Politico in an interview last year that he did not intend to leave the company.
Novo said Jørgensen would remain in his article “during a period to support a smooth transition to new leadership”. He added that the search for his replacement was underway and that an ad would be made in due time.
Last month, the long -standing chief of the commercial and commercial affairs of the pharmaceutical giant, Camilla Sylvest, also withdrew.
Politices
